Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1089 studies found for:    "Glioblastoma"
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
2 Active, not recruiting Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
3 Not yet recruiting Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
Conditions: Glioblastoma;   Grade IV Astrocytoma;   Glioblastoma Multiforme
Intervention: Drug: MDNA55
4 Not yet recruiting Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer
Intervention: Drug: VAL-083
5 Active, not recruiting Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)
Conditions: Glioblastoma Multiforme;   Glioblastoma
Intervention: Biological: Single arm, open-label
6 Terminated Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme
Intervention: Drug: FDOPA PET
7 Recruiting Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme;   Glioblastoma - Category
Interventions: Drug: Bevacizumab;   Procedure: Magnetic Resonance Spectroscopy (MRS);   Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS)
8 Active, not recruiting Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: DNA methylation analysis
9 Recruiting Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Glioma;   Astrocytoma;   Brain Tumor
Interventions: Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy;   Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
10 Recruiting Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   MGMT-unmethylated Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Features;   Giant Cell Glioblastoma;   Glioblastoma Multiforme
Interventions: Radiation: Radiation Therapy;   Biological: Personalized NeoAntigen Vaccine
11 Recruiting NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Biological: Bevacizumab;   Device: NovoTTF-l00A;   Other: Quality of Life Assessment
12 Completed Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Conditions: Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma
Interventions: Drug: XL184;   Drug: temozolomide;   Radiation: Radiation Therapy
13 Active, not recruiting Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Glioblastoma Multiforme
Interventions: Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose);   Drug: Bevacizumab
14 Not yet recruiting Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Conditions: Glioblastoma;   Glioblastoma Multiforme
Interventions: Drug: 5-day TMZ;   Drug: 21-day TMZ;   Biological: PEP-CMV;   Drug: Tetanus-Diphtheria booster;   Drug: Tetanus Pre-Conditioning
15 Active, not recruiting A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Conditions: Glioblastoma;   GBM;   Glioblastoma Multiforme
Interventions: Drug: Ascorbate;   Drug: Temozolomide;   Radiation: Radiation therapy
16 Recruiting Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma
Conditions: Glioblastoma;   Glioblastoma Multiforme
Intervention: Procedure: MRI
17 Active, not recruiting PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Conditions: Glioblastoma;   GBM;   Glioblastoma Multiforme
Intervention: Drug: PF-00299804
18 Recruiting Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Conditions: Glioblastoma;   Recurrent Glioblastoma;   Brain Tumor
Intervention: Drug: Tesevatinib
19 Recruiting TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Conditions: Glioblastoma Multiforme;   Glioblastoma;   Malignant Glioma;   GBM
Interventions: Drug: Bevacizumab;   Device: Optune;   Other: Brain MRI;   Other: Quality of Life Questionnaires
20 Active, not recruiting PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
Conditions: Glioblastoma;   Cancer of Brain and Nervous System;   Glioblastoma Multiforme
Interventions: Drug: Temozolomide;   Procedure: Stereotactic Radiosurgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years